DDInter1744 DDInter740
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Tamoxifen {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Tamoxifen {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Flecainide
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Flecainide
Tamoxifen {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Tamoxifen {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Tamoxifen {u} (Compound) causes {v} (Side Effect) Dizziness
Dizziness {u} (Side Effect) is caused by {v} (Compound) Mefloquine
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is upregulated by {v} (Compound) Flecainide
Tamoxifen {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is regulated by {v} (Gene) PHGDH
PHGDH {u} (Gene) is upregulated by {v} (Compound) Flecainide
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) resembles Flecainide (Compound)
Tamoxifen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Tamoxifen (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Tamoxifen (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Flecainide (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Flecainide (Compound)
Tamoxifen (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Tamoxifen (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Tamoxifen (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Mefloquine (Compound) and Mefloquine (Compound) resembles Flecainide (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Flecainide (Compound)
Tamoxifen (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is regulated by PHGDH (Gene) and PHGDH (Gene) is upregulated by Flecainide (Compound)